melatonin in patients with COVID-19

Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200506047323N7

Enrollment

Registered

2021-02-16

Start date

2021-02-28

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19, virus not identified

Interventions

Intervention 1: Control group: Group A will be patients receiving standard treatment of COVID-19 according to the Ministry of Health's protocol. Intervention 2: Intervention group: Group B will be pat

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Definitive diagnosis of COVID-19 based on RT-PCR or/and serological testing, Age >20 years. Diagnosis of pneumonia based on pulmonary CT-Scan. Admitted in the intensive care unit. Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm.

Exclusion criteria

Exclusion criteria: Patients with underlying disorder, including convulsive disorders, hepatic disease and disorder, renal disease and disorder. Intubated patients and use of mechanical ventilation. pregnancy and breastfeeding.

Design outcomes

Primary

Measure	Time frame
Arterial blood gas (ABG). Timepoint: Before intervention and daily during the intervention. Method of measurement: Biochemical laboratory.;C-Reactive Protein (C-RP). Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: C-RP kit.;Ferritin. Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: Biochemical laboratory.;Lactate dehydrogenase (LDH). Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: Biochemical laboratory.	—

Measure

Time frame

Arterial blood gas (ABG). Timepoint: Before intervention and daily during the intervention. Method of measurement: Biochemical laboratory.;C-Reactive Protein (C-RP). Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: C-RP kit.;Ferritin. Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: Biochemical laboratory.;Lactate dehydrogenase (LDH). Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: Biochemical laboratory.

—

Secondary

Measure	Time frame
Need for mechanical ventilation. Timepoint: Daily. Method of measurement: Checklist.;Patients consciousness level. Timepoint: Daily. Method of measurement: Glasgow Coma Scale (GCS).;Mortality rate. Timepoint: Daily. Method of measurement: Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Fathalipour

Bandare-abbas University of Medical Sciences

m.fathalipour@hums.ac.ir+98 76 3371 0406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 23, 2026